Akèy › Limfom selil mantèl › New York › New York City
Etid klinik pou Limfom selil mantèl nan New York City, NY
12 etid pou Limfom selil mantèl ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Ap rekriteFaz 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Weill Cornell Medical Center, New York
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Ap rekriteFaz 1/2
- Research Site, New York
- Research Site, New York
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Ap rekriteFaz 3
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Ap rekriteFaz 1/2
- Research Site, New York
A Study of ARC-02 in B-cell NHL
Ap rekriteFaz 1
- NYU Langone, New York
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center - Bergen, New York
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
Study of SGR-1505 in Mature B-Cell Neoplasms
Ap rekriteFaz 1
- Weill Cornell, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, New York
Etid Limfom selil mantèl nan lòt vil
- Houston, TX15 etid
- Baldwin Park, CA15 etid
- Durham, NC13 etid
- Seattle, WA12 etid
- Milwaukee, WI12 etid
- Boston, MA11 etid
- Nashville, TN11 etid
- Columbus, OH11 etid
- Chicago, IL10 etid
- Rochester, MN9 etid
- Portland, OR9 etid
- St. Louis, MO8 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.